Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials
ConclusionsThe use of ubrogepant as an acute treatment of episodic migraine in adults led to a greater percentage of freedom from pain and absence of the most bothersome symptoms at 2 h post-dose. Short-term use of ubrogepant was not related to an increased risk for adverse events. Further studies are needed to evaluate efficacy and safety for long-term use and in specific subgroups of patients.
Source: CNS Drugs - Category: Neurology Source Type: research
More News: Chronic Pain | Clinical Trials | Databases & Libraries | Genetics | Headache | Migraine | Neurology | Pain | Study